Latest News-CliniExpert

Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology

NEW YORK--(BUSINESS WIRE) June 03, 2020 -- Pfizer Inc. (NYSE: PFE) announced today that JAMA Dermatology has published complete results from the second Phase 3 monotherapy pivotal study (JADE MONO-2)

BerGenBio Confirms First Covid-19 Patient Dosed With Bemcentinib in ACCORD Trial

Bergen, Norway - 02 June 2020 -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces

Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF- 100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress

MIAMI, June 02, 2020 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTICS Holding AG (SIX:RLF) (Relief) and its U.S. partner, NeuroRx, Inc. today announced treatment of the first patients with RLF-100 at the Unive

Trevena Announces Collaboration with Imperial College London to Evaluate TRV027 in COVID-19 Patients

CHESTERBROOK, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with cen

AbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment

VANCOUVER, British Columbia, June 1, 2020 -- AbCellera today announced that LY-CoV555, the lead antibody from the collaboration between AbCellera and Eli Lilly and Company (Lilly), has entered into hu

Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun. 1, 2020 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19

Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids

BASEL, Switzerland, June 01, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it has submitted a New

Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans

INDIANAPOLIS, June 1, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight

BioMarin Provides Highlights of 4 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

SAN RAFAEL, Calif., May 31, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocog

Moderna Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 29, 2020 -- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new genera

Investigational Magrolimab in Combination With Azacitidine Demonstrates Durable Activity in Previously-Untreated Myelodysplastic Syndrome and Acute Myeloid Leukemia

FOSTER CITY, Calif.--(BUSINESS WIRE)--May 29, 2020 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced updated results from a single-arm, open-label Phase 1b trial of magrolimab, an investigationa

Sumitovant Biopharma Announces Myovant Sciences’ Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine

LONDON and NEW YORK, May 29, 2020 /PRNewswire/ -- Sumitovant Biopharma Ltd. announced that Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, and one